BU Fundamental Analysis - BURCON NUTRASCIENCE CORP

Fundamental Rating

Taking everything into account, BU scores 2 out of 10 in our fundamental rating. BU was compared to 27 industry peers in the Chemicals industry. BU has a bad profitability rating. Also its financial health evaluation is rather negative. BU shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BU has reported negative net income.
BU had a negative operating cash flow in the past year.
In the past 5 years BU always reported negative net income.
In the past 5 years BU always reported negative operating cash flow.

1.2 Ratios

BU has a Return On Assets of -45.26%. This is in the lower half of the industry: BU underperforms 77.78% of its industry peers.
Looking at the Return On Equity, with a value of -8604.73%, BU is doing worse than 81.48% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-45.26%
ROE	-8604.73%
ROIC	N/A

ROA(3y)-113.59%

ROA(5y)-75.48%

ROE(3y)-292.02%

ROE(5y)-182.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BU has more shares outstanding
The number of shares outstanding for BU has been increased compared to 5 years ago.
BU has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -9.45, we must say that BU is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.45, BU is not doing good in the industry: 74.07% of the companies in the same industry are doing better.
BU has a Debt/Equity ratio of 104.05. This is a high value indicating a heavy dependency on external financing.
BU has a worse Debt to Equity ratio (104.05) than 81.48% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	104.05
Debt/FCF	N/A
Altman-Z	-9.45

ROIC/WACCN/A

WACC9.32%

2.3 Liquidity

BU has a Current Ratio of 0.25. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.25, BU is doing worse than 77.78% of the companies in the same industry.
A Quick Ratio of 0.21 indicates that BU may have some problems paying its short term obligations.
BU's Quick ratio of 0.21 is on the low side compared to the rest of the industry. BU is outperformed by 81.48% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.25
Quick Ratio	0.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BU have decreased strongly by -163.63% in the last year.
The Revenue has grown by 190.04% in the past year. This is a very strong growth!
BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.28% yearly.

EPS 1Y (TTM)-163.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.35%

Revenue 1Y (TTM)190.04%

Revenue growth 3Y30.91%

Revenue growth 5Y66.28%

Sales Q2Q%792.98%

3.2 Future

BU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 224.01% yearly.
The Revenue is expected to grow by 228.16% on average over the next years. This is a very strong growth

EPS Next Y-803.01%

EPS Next 2Y224.01%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year153.85%

Revenue Next 2Y228.17%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 0.28, the valuation of BU can be described as very cheap.
BU's Price/Forward Earnings ratio is rather cheap when compared to the industry. BU is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, BU is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.28

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BU's earnings are expected to grow with 224.01% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y224.01%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BU!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BURCON NUTRASCIENCE CORP

TSX:BU (1/20/2026, 7:00:00 PM)

1.83

+0.13 (+7.65%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)11-12 2025-11-12/amc

Earnings (Next)02-12 2026-02-12

Inst Owners5.83%

Inst Owner ChangeN/A

Ins Owners31.02%

Ins Owner ChangeN/A

Market Cap23.22M

Revenue(TTM)803.70K

Net Income(TTM)-11.11M

Analysts84.44

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-359.08%

Min EPS beat(2)-443.69%

Max EPS beat(2)-274.48%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)17.69%

Min Revenue beat(2)-30.64%

Max Revenue beat(2)66.02%

Revenue beat(4)1

Avg Revenue beat(4)-37.08%

Min Revenue beat(4)-95.36%

Max Revenue beat(4)66.02%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.28
P/S	28.89
P/FCF	N/A
P/OCF	N/A
P/B	179.88
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.98

EYN/A

EPS(NY)6.58

Fwd EY359.66%

FCF(TTM)-0.62

FCFYN/A

OCF(TTM)-0.56

OCFYN/A

SpS0.06

BVpS0.01

TBVpS-0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.26%
ROE	-8604.73%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-113.59%

ROA(5y)-75.48%

ROE(3y)-292.02%

ROE(5y)-182.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	104.05
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	46.09%
Cap/Sales	95.93%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.25
Quick Ratio	0.21
Altman-Z	-9.45

F-Score4

WACC9.32%

ROIC/WACCN/A

Cap/Depr(3y)68.17%

Cap/Depr(5y)195.49%

Cap/Sales(3y)82.83%

Cap/Sales(5y)124.04%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-163.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.35%

EPS Next Y-803.01%

EPS Next 2Y224.01%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)190.04%

Revenue growth 3Y30.91%

Revenue growth 5Y66.28%

Sales Q2Q%792.98%

Revenue Next Year153.85%

Revenue Next 2Y228.17%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-1.09%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year40.58%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-51.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.69%

OCF growth 3YN/A

OCF growth 5YN/A

BURCON NUTRASCIENCE CORP / BU.CA FAQ

What is the fundamental rating for BU stock?

ChartMill assigns a fundamental rating of 2 / 10 to BU.CA.

What is the valuation status for BU stock?

ChartMill assigns a valuation rating of 3 / 10 to BURCON NUTRASCIENCE CORP (BU.CA). This can be considered as Overvalued.

What is the profitability of BU stock?

BURCON NUTRASCIENCE CORP (BU.CA) has a profitability rating of 0 / 10.

What is the expected EPS growth for BURCON NUTRASCIENCE CORP (BU.CA) stock?

The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BU.CA) is expected to decline by -803.01% in the next year.

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BURCON NUTRASCIENCE CORP / BU.CA FAQ

What is the fundamental rating for BU stock?

What is the valuation status for BU stock?

What is the profitability of BU stock?

What is the expected EPS growth for BURCON NUTRASCIENCE CORP (BU.CA) stock?